The Pharma Letter

In Focus

Mega-mergers could be back in pharma sector, but is Pfizer bid for AstraZeneca likely to succeed?

This weekend’s revelation about a possible acquisition of Anglo-Swedish drug major AstraZeneca by the world’s largest pharma company Pfizer for around $100 billion (£60 billion) would suggest that the mega-merger mentality could be back on the pharmaceutical agenda, which has been absent since before 2010.

Latest Pharmaceutical News

Latest Biotechnology News

Latest Generics News

Boardroom

Mergers & Acquisitions

Pharma M&A deals in 2013 down, but values marginally higher

Pharma M&A deals in 2013 down, but values marginally higher

Merger and acquisition activity in the pharmaceutical, biotechnology and generic drugs sectors continued steadily in 2013, but the days of mega mergers are clearly over as the number of giant players has diminished.

Back to top